Administration of Etesevimab

retired

URL

http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.4025

Version

20220714

PublisherClinical ArchitectureDate2023-06-21T18:16:37-04:00Purpose

(Clinical Focus: This set of values contains terms related to administration of etesevimab.),(Data Element Scope: ),(Inclusion Criteria: Includes introduction of etesevimab into central or peripheral veins via open or percutaneous routes.),(Exclusion Criteria: Excludes administration of other monoclonal antibodies (e.g., abciximab, infliximab) and routes of administration that do not involve open or percutaneous procedures (i.e. oral administration).)

Expansion

Expansion error

Can't resolve code system: http://www.cms.gov/Medicare/Coding/ICD10

{
  "compose" : {
    "exclude" : [ ],
    "include" : [ {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "extension" : [ {
        "extension" : [ {
          "valueString" : "concept",
          "url" : "path"
        }, {
          "url" : "count",
          "valueInteger" : 2
        } ],
        "url" : "http://health-samurai.io/extensions/excised-data"
      } ]
    } ]
  },
  "date" : "2023-06-21T18:16:37-04:00",
  "meta" : {
    "versionId" : "5",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [ "http://hl7.org/fhir/StructureDefinition/shareablevalueset", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm" ]
  },
  "publisher" : "Clinical Architecture",
  "jurisdiction" : [ {
    "coding" : [ {
      "system" : "urn:iso:std:iso:3166",
      "code" : "US"
    } ]
  } ],
  "purpose" : "(Clinical Focus: This set of values contains terms related to administration of etesevimab.),(Data Element Scope: ),(Inclusion Criteria: Includes introduction of etesevimab into central or peripheral veins via open or percutaneous routes.),(Exclusion Criteria: Excludes administration of other monoclonal antibodies (e.g., abciximab, infliximab) and routes of administration that do not involve open or percutaneous procedures (i.e. oral administration).)",
  "name" : "AdministrationOfEtesevimab",
  "experimental" : false,
  "resourceType" : "ValueSet",
  "expansion" : {
    "contains" : [ {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "XW033E6",
      "display" : "Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6",
      "version" : "2024"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "XW043E6",
      "display" : "Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6",
      "version" : "2024"
    } ],
    "total" : 2,
    "identifier" : "urn:uuid:80ad42e6-9cb8-4fa4-af35-3389b0d36ef4",
    "timestamp" : "2024-06-14T16:16:55-04:00"
  },
  "title" : "Administration of Etesevimab",
  "extension" : [ {
    "valueString" : "Clinical Architecture",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author"
  }, {
    "valueDate" : "2023-06-21",
    "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate"
  }, {
    "valueDate" : "2022-07-14",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate"
  }, {
    "url" : "http://health-samurai.io/extensions/source",
    "valueCode" : "db"
  } ],
  "status" : "retired",
  "id" : "2.16.840.1.113883.3.3616.200.110.102.4025",
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.4025",
  "identifier" : [ {
    "system" : "urn:ietf:rfc:3986",
    "value" : "urn:oid:2.16.840.1.113883.3.3616.200.110.102.4025"
  } ],
  "version" : "20220714"
}